Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving CAR-T Cell Therapy

被引：0
|
作者：
Jodon, Gray [1 ]
Colton, Meryl [1 ]
Abbott, Diana [2 ]
Cai, Anthony [3 ]
Haverkos, Brad M. [4 ]
Morgan, Rustain [3 ]
Kamdar, Manali [5 ]
机构：
[1] Univ Colorado Canc Ctr, Aurora, CO USA
[2] Univ Colorado Denver, Dept Biostat & Bioinformat, Aurora, CO USA
[3] Univ Colorado Anschutz Med Campus, Aurora, CO USA
[4] Ohio State Univ, Div Hematol Hematol Malignancies & Stem Cell Tran, Aurora, CO USA
[5] Univ Colorado Canc Ctr, Div Hematol Hematol Malignancies & Stem Cell Tran, Denver, CO USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146613
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy
    Jodon, Gray
    Colton, Meryl D.
    Abbott, Diana
    Cai, Anthony
    Haverkos, Bradley
    Morgan, Rustain
    Kamdar, Manali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (01): : 49 - 56
  • [2] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, : 869 - 876
  • [3] Tisagenlecleucel: CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
    Saha, Aditi
    Jhaveri, Khushali
    Sarfraz, Humaira
    Chavez, Julio C.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023,
  • [4] A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy
    Hayashino, K.
    Nishimori, H.
    Fujiwara, K.
    Kondo, K.
    Matsubara, C.
    Terao, T.
    Kitamura, W.
    Kamoi, C.
    Seike, K.
    Fujiwara, H.
    Asada, N.
    Ennishi, D.
    Fujii, K.
    Fujii, N.
    Matsuoka, K-I.
    Maeda, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1602 - S1603
  • [5] Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma
    Lin, Manisha
    Weiss, Jonathan
    Phillips, Tycel J.
    Sano, Dahlia
    Carty, Shannon A.
    Ghosh, Monalisa
    Ahmed, Iman
    Nachar, Victoria
    Hutton, David
    Karimi, Yasmin H.
    BLOOD, 2023, 142
  • [6] Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy
    Perrone, Salvatore
    Lopedote, Paolo
    Levis, Mario
    Di Rocco, Alice
    Smith, Stephen Douglas
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 215 - 232
  • [7] The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma
    Lutfi, Forat
    Kansagra, Ankit
    Ali, Moaath Mustafa
    Bukhari, Ali
    Siglin, Jonathan
    Yan, Jingsheng
    Samanta, Santanu
    Holtzman, Noa G.
    Gottlieb, David
    Kim, Dong Won
    Lee, Seung-Tae
    Kocoglu, Mehmet Hakan
    Yared, Jean A.
    Hardy, Nancy M.
    Molitoris, Jason
    Mohindra, Pranshu
    Rapoport, Aaron P.
    Dahiya, Saurabh
    BLOOD, 2020, 136
  • [8] Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
    Ramos, Carlos A.
    Grover, Natalie S.
    Beaven, Anne W.
    Lulla, Premal D.
    Wu, Meng-Fen
    Ivanova, Anastasia
    Wang, Tao
    Shea, Thomas C.
    Rooney, Cliona M.
    Dittus, Christopher
    Park, Steven I.
    Gee, Adrian P.
    Eldridge, Paul W.
    McKay, Kathryn L.
    Mehta, Birju
    Cheng, Catherine J.
    Buchanan, Faith B.
    Grilley, Bambi J.
    Morrison, Kaitlin
    Brenner, Malcolm K.
    Serody, Jonathan S.
    Dotti, Gianpietro
    Heslop, Helen E.
    Savoldo, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3794 - +
  • [9] CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Messori, Andrea
    Damuzzo, Vera
    Leonardi, Luca
    Agnoletto, Laura
    Chiumente, Marco
    Mengato, Daniele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : 490 - 491
  • [10] Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
    Liu, Yang
    Yan, Zhiling
    Wu, Qingyun
    Chen, Chong
    Cao, Jiang
    Li, Zhenyu
    Xu, Kailin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S49
12345